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Abstract
Purpose: Systematic evaluation of the potential relationship between the common genetic variants of CYP21A2 and
hormone levels.
Methods: The relationships of CYP21A2 intron 2 polymorphisms and haplotypes with diverse baseline and stimulated blood
hormone levels were studied in 106 subjects with non-functioning adrenal incidentaloma (NFAI). The rationale for using
NFAI subjects is dual: i) their baseline hormone profiles do not differ from those of healthy subjects and ii) hormone levels
after stimulation tests are available.
Results: The carriers (N = 27) of a well-defined CYP21A2 haplotype cluster (c5) had significantly elevated levels of cortisol
(p = 0.0110), and 17-hydroxyprogesterone (p = 0.0001) after ACTH stimulation, and 11-deoxycortisol after metyrapone
administration (p = 0.0017), but the hormone values were in normal ranges. In addition, the carriers (N = 33) of the C allele of
the rs6462 polymorphism had a higher baseline aldosterone level (p = 0.0006). The prevalence of these genetic variants of
CYP21A2 did not differ between NFAI and healthy subjects.
Conclusions: The common CYP21A2 variants presumably exert the same effect on hormone levels in the healthy and
disease-affected populations. Therefore, they may contribute to complex diseases such as some cardiovascular diseases, and
may influence the genotype-phenotype correlation in patients with congenital adrenal hyperplasia (CAH) including the
individual need for hormone substitution.
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Introduction
Human steroid 21-hydroxylase enzyme (cytochrome P450c21)
is expressed uniquely in the adrenal cortex, catalyzes the 21-
hydroxylation of progesterone to 11-deoxycorticosterone and 17-
hydroxyprogesterone (17-OHP) to 11-deoxycortisol in the biosyn-
thesis of mineralocorticoids (aldosterone) and glucocorticoids
(cortisol) [1], and is encoded by the CYP21A2 gene (OMIM:
613815) [2]. CYP21A2 is located together with the complement
component 4A and 4B genes (C4A and C4B) in a multi-allelic,
complex and tandem copy number variation (CNV), called
RCCX CNV, and, in a wider sense, in the major histocompat-
ibility complex of chromosome 6 [3,4]. RCCX CNV also
comprises the duplicated non-functional pseudogene of steroid
21-hydroxylase (CYP21A1P). In addition to the single copy of
CYP21A2, zero, one or two copies of CYP21A1P can reside in
one chromosome, depending on the copy number of the repeated
region in RCCX CNV [5]. Rarely, there is no CYP21A2, or there
is more than one CYP21A2 copy on one chromosome, usually
resulting in one or three gene copies in the diploid state [6,7]. In
the majority of cases, classical congenital adrenal hyperplasia
(CAH, OMIM: 201910) is caused by the complete lack of
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functional CYP21A2 (CAH is divided in two main forms; a
classical one with severe symptoms and a non-classical one with
milder symptoms) [8].
Adrenal incidentalomas have become a rather common finding
in clinical practice since the widespread introduction of abdominal
imaging procedures such as computed tomography (CT) and
ultrasonography for non-endocrinological reasons. The current
prevalence of unsuspected adrenal tumors range between 1% and
6% [9]. Pheochromocytomas, adrenocortical carcinomas and
adrenocortical hormone overproduction syndromes (including
subclinical cortisol hypersecretion described as subclinical Cush-
ing’s syndrome) are relatively rare, and the vast majority of
adrenal tumors are benign non-functioning adrenal incidentalo-
mas (NFAIs) [10,11]. NFAI confers a slightly elevated risk of
malignancy, but the hormone profiles of subjects with NFAI do
not differ from those in subjects without adrenal lesions [12].
There are numerous hypotheses about the development of NFAI
including, among others, the contribution of CYP21A2. An
elevated 17-OHP response to adrenocorticotrophic hormone
(ACTH) administration, which is a characteristic of CAH, has
been also observed in approximately half of the subjects with
NFAI [13,14]. Consistent with these data, the heterozygote
carriers of loss-of-function mutations of CYP21A2 occurred more
frequently in a study involving 50 NFAI subjects [15]. However,
the role played by CYP21A2 in the epidemiology and pathogen-
esis of NFAI is controversial, and the potential mechanism is
unexplored [16].
In spite of recent advances in the discovery of CNVs [17], the
complex, multi-allelic CNVs and their gene contents such as
RCCX CNV and CYP21A2 are underexplored due to technical
difficulties [18]. While numerous studies have explored CYP21A2
in the context of CAH, little information is available on the genetic
variants of CYP21A2 in correlation with circulating hormone
levels in healthy or NFAI subjects. Variants of the full-length
CYP21A2 haplotype have been recently determined largely by
molecular haplotyping [4]. Furthermore, CYP21A2 intron 2 has
been proven to be under positive selection in a healthy European
population [19], implying that this subregion can exert an
influence on steroid hormone levels. Moreover, the gene copy
number of C4B (a genetic element of RCCX CNV) is associated
with hormone levels in subjects with NFAI [20].
The primary aim of the current study is to reveal the putative
relationship of common CYP21A2 haplotypes (and polymor-
phisms) with baseline and stimulated hormone levels (the direct
and causal relationship between CYP21A2 and its metabolites is
highly probable). We investigated the haplotypes of CYP21A2
intron 2 and the 59-end of exon 3 as ‘‘complex genetic markers’’
[21], because they characterize well the full-length CYP21A2
haplotypes [19]. A population of subjects with NFAI was applied
to this, because the baseline hormone profiles of NFAI subjects do
not differ from those of healthy subjects, but the NFAI subjects
had wider available hormone profiles including hormone levels
after ACTH and metyrapone administrations (such administra-
tions to healthy subjects conflict with medical ethics [22]). In
addition, the genetic differences between the NFAI and healthy
control subjects were also investigated (we did not examine the
hormone levels of healthy subjects, therefore, there was no case-
control approach from the viewpoint of hormone levels), with the
secondary aim of evaluating the putative predisposing and
protecting CYP21A2 variant(s) for NFAI using the allele
frequencies of genetic variants.
Materials and Methods
Subjects
A total of 125 subjects with adrenal incidentaloma diagnosed by
abdominal CT or ultrasonography were enrolled into this
retrospective study at the 2nd Department of Internal Medicine,
Semmelweis University (Budapest, Hungary) (Table 1). All NFAI
subjects had European origin, and were genetically unrelated. The
presence of clinically overt hormone production, aldosterone-
secreting and cortisol-producing tumors (including subclinical
Cushing’s syndrome), pheochromocytoma and adrenal carcinoma,
and adrenal surgery were exclusion criteria. In addition, 68
healthy control subjects (female: 65.2%, median age: 37.5,
interquartile range of age: 31–43), without any clinical signs of
hormone overproduction or metabolic disorders, were enrolled.
The study protocol was approved by the Hungarian Health
Science Council (84-358/2008-1018EKU) and by the Institutional
Ethics Committee of Semmelweis University. All subjects gave
written informed consent according to the Declaration of Helsinki
[22].
Hormone measurements
Hormonal evaluation included morning (at 0800–0900 h)
serum cortisol, corticosterone, 17-OHP, plasma ACTH, aldoste-
rone and midnight (at 2400 h) cortisol. Serum cortisol, corticoste-
rone, 17-OHP and plasma aldosterone concentrations were
measured after ACTH administration (a single dose of Cortrosyn
or Synacthen depot, 1 mg im), while serum cortisol level was also
determined after a 1 mg dexamethasone suppression test. Plasma
ACTH and 11-deoxycortisol levels were measured after metyra-
pone administration (a single dose, 30 mg/kg bodyweight, orally).
Plasma ACTH and serum cortisol concentrations were measured
by electrochemoluminescent immunoassays (Elecsys, Cobas E411,
Roche, Basel, Switzerland). Plasma aldosterone, serum corticoste-
rone, dehydroepiandrosterone sulfate (DHEA-S), 11-deoxycortisol
and 17-OHP levels were determined with radioimmunoassays
[14], and polyclonal antibodies for these measurements were the
generous gifts from professor Paul Vecsey (Institute of Pharma-
cology, University of Heidelberg, Germany). Plasma renin activity
was determined under resting conditions using a commercially
available kit (Rianen, DuPont, Boston, MA, USA).
Genetic analyses
The gene copy numbers of C4 and CYP21A2, and the
haplotypes of intron 2 and the 59-part of exon 3 of CYP21A2
(the region will be henceforth denoted as ‘CYP21A2 intron 29)
were determined as we have previously described [4,19,23].
Briefly, C4-type-specific quantitative PCRs (qPCR) [23], and
CYP21-gene-specific qPCR [19] were applied to determine gene
copy numbers. Haplotypic or genotypic nested polymerase chain
reaction (PCR) products of CYP21A2 were generated from the
templates of allele-specific long-range PCRs [4], then CYP21A2
intron 2 was sequenced by SEQ_12F_v2 and SEQ_16R
sequencing primers [19]. In addition to the CAH mutations
detected by the aforementioned methods, the six commonly
occurring CAH mutations (I172N, exon 6 cluster, p.V281L,
p.L307insT, p.Q318* and p.R356W) were also determined [24].
Experimentally indeterminable haplotypic CYP21A2 intron 2
sequences were resolved by the PHASE software v2.1.1 [25,26]. A
phylogenetic tree of the CYP21A2 intron 2 haplotype variants and
Hardy-Weinberg equilibrium (HWE) were calculated by Arlequin
v3.5 [27]. Linkage disequilibrium (LD) was evaluated using DnaSP
v5.10.01 [28], and was visualized by Haploview v4.2 [29].
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Statistical analyses
To find the relationship between hormone levels and CYP21A2
intron 2 haplotypes, the haplotype tree of CYP21A2 intron 2 was
scanned by TreeScan v1.0 [30]. Traditional statistical analyses
were performed with G*Power v3.1.3 [31], SPSS v20 (SPSS Inc.,
Chicago, IL, USA) and STATISTICA v8 (Statsoft inc. Tulsa, OK,
USA) software. Briefly, the outliers of hormone data were filtered
based on a two-sided standard deviation, and the normal
distributions of hormone datasets were tested by the Kolmo-
gorov-Smirnov test. The datasets passing the normality test were
analysed by unpaired t-test and analysis of variance (ANOVA),
and the datasets with non-normal distribution were examined by
Mann-Whitney and Kruskal-Wallis tests. The genetic associations
adjusted for gender, age, tumor diameter and body mass index
(BMI) and correlations between steroid hormone levels and
adjusting variables were calculated by multiple logistic regression
analysis with cutoff values obtained by receiver operating
characteristic (ROC) analysis. All tests were two-tailed.
Results
Genetic exclusions and the validity of genetic data
In 125 enrolled subjects with NFAI (Table 1), 12 subjects had
CYP21A2 CAH mutations in a carrier state (7 of 12 subjects
carried a p.V281L mutation, which causes non-classical CAH in
homozygous form) and 7 subjects with more than two CYP21A2
gene copies were observed. These 19 subjects were excluded from
further analyses of the current study in order to avoid the potential
disturbing effect of these genetic variants on hormone levels. In
212 chromosomes of the remaining 106 subjects, 116 (54.7%)
CYP21A2 intron 2 haplotypes were experimentally determined
(by molecular haplotyping), and 88 (41.5%) haplotypes were
resolved in silico. Eight (3.8%) haplotypes of four subjects fell
below the confidence probability threshold of in silico reconstruc-
tion, and were unresolved. Because the combined molecular and
inferred haplotyping approach ensures highly reliable results [4],
all resolved haplotypes were regarded as valid, but the four
subjects carrying unresolved haplotypes were excluded, and
therefore 102 subjects were included in the haplotype-based
analyses. The healthy control subjects went through the same
genetic exclusion process, resulting in 54 studied subjects (7
subjects harbored CAH mutations in a carrier state, 6 subjects had
more than two CYP21A2 gene copies, and CYP21A2 haplotypes
were unresolved in 1 subject out of 68 enrolled healthy subjects.
Six out of 7 subjects with CAH mutations carried the non-classical
p.V281L mutation.). There were no significant differences in
either the prevalence of CAH mutation carriers (Fisher’s exact test:
p = 1.0000) or the prevalence of the individuals with more than
two CYP21A2 gene copies (Fisher’s exact test: p = 0.5516) between
the populations of NFAI and healthy control subjects. Overall, 26
kinds of CYP21A2 intron 2 haplotype were observed in NFAI
subjects (Table S1), 4 kinds were unique for the NFAI subjects,
and 8 kinds did not occur or were excluded in a previous exclusion
step due to CAH mutations in the NFAI subjects, but were
observed in recent studies [4,19]. The 26 different CYP21A2
intron 2 haplotype variants adequately marked the full-length
CYP21A2 haplotype variants (Table S1), and the haplotypes did
not deviate from HWE in either population (NFAI: p = 0.0595
control: p = 0.2234). There were no significant differences in
haplotype distributions (Chi2 test: p = 0.9471) and in the preva-
lence of alleles of CYP21A2 intron 2 polymorphisms between the
subjects with NFAI and the healthy control subjects (Fisher’s exact
test: p = 0.3129–1.000, Chi2 test of site 605 (rs6451): p = 0.2505,
the polymorphisms (sites) are numbered from the start of the
CYP21A2 coding region in the sequence of NT_007592.15:
31945792-31949720).
Searching for the relationship between hormone levels
and CYP21A2 intron 2 haplotypes
The CYP21A2 intron 2 haplotypes or the clusters of the
haplotypes having different hormone levels than other haplotypes
or clusters were searched by a tree scanning method in subjects
Table 1. Characteristics of Hungarian subjects with non-functioning adrenal incidentaloma before genetic exclusions.
All subjects (N=125)
Female (%) 76.0
Age (year) 53 (46.5–61)
BMI (kg/m2) 29.2 (25.8–32.4)
Diameter of adenoma (mm) 23.5 (15.0–32.0)
ACTH (pmol/l) 3.82 (2.60–5.29)
metyrapone-induced ACTH (pmol/l) 40.3 (15.5–63.6)
DHEA-S (mmol/l) 3.94 (2.47–7.13)
morning cortisol (nmol/l) 340 (276–421)
midnight cortisol (nmol/l) 83 (55–138)
LDDST cortisol (nmol/l) 55 (28–74)
Hypertension (%) 78.8
DM 2 (%) 32.0
CAH mutation carriers (%) 9.6a
,2 CYP21A2 gene copies (%) 5.6b
BMI – body mass index, ACTH – adrenocorticotrophic hormone, DHEA-S – dehydroepiandrosterone sulfate, LDDST – low dose dexamethasone test, DM 2– type 2
diabetes mellitus, CAH – congenital adrenal hyperplasia and CYP21A2– human steroid 21-hydroxlylase gene. Values are medians except for percentage values, and
interquartile ranges are in parentheses.
aThere was no significant difference in prevalence (Fisher’s exact test: p = 1.0000) compared to healthy Hungarian control subjects.
bThere was no significant difference in prevalence (Fisher’s exact test: p = 0.5516) compared to healthy Hungarian control subjects.
doi:10.1371/journal.pone.0107244.t001
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with NFAI (N= 102). Briefly, this method splits the phylogenetic
tree of CYP21A2 intron 2 haplotypes into two parts in all possible
ways, and serially tests the differences of hormone levels of NFAI
subjects between the two parts. Two clusters of evolutionary-
related CYP21A2 intron 2 haplotypes (sharing highly similar allele
compositions inside the clusters) showed multiple significances in
the steroid hormone levels (Figure 1). The cluster of ih04, ih05,
ih09 and ih34 haplotypes named c5 for the most prevalent
haplotype of the cluster (ih05) significantly differed in ACTH-
induced cortisol, ACTH-induced 17-OHP and metyrapone-
blocked 11-deoxycortisol levels. The c5 haplotypes occurred with
14.2% prevalence in the CYP21A2 intron 2 haplotypes of subjects
with NFAI, and this prevalence did not deviate (Fisher’s exact test:
p = 0.4240) from the prevalence (18.5%) observed in the healthy
population (N= 54). The cluster of ih07 and ih08 haplotypes
termed c8 significantly differed in ACTH-induced cortisol and
ACTH-induced aldosterone levels. The c8 haplotypes occurred
with an 8.8% prevalence in subjects with NFAI, and it also did not
significantly deviate (Fisher’s exact test: p = 0.8308) from that of
the healthy population (7.4%).
Relationship between hormone levels and the CYP21A2
intron 2 haplotype clusters
To further investigate the relationship between hormone levels
and the revealed haplotype clusters, the subjects with NFAI were
divided into three genotype groups based on the results of tree
scanning (Table 2); the carriers of c5 haplotypes (N= 27), the
carriers of c8 haplotypes (N= 16) and the NFAI subjects carrying
neither of these two haplotype clusters (N= 57). Only two NFAI
subjects were carriers of both haplotype clusters, necessitating their
exclusion from statistical analysis. The majority of the hormone
values were far inside normal ranges; however, some of them were
close to the boundaries of normal ranges [32]. The baseline
morning levels of cortisol, 17-OHP, corticosterone, DHEA-S,
ACTH and midnight level of cortisol did not differ significantly
between the genotype groups. In contrast, significant differences
were found in morning aldosterone, ACTH-induced cortisol,
ACTH-induced 17-OHP, metyrapone-blocked 11-deoxycortisol,
and metyrapone-blocked ACTH levels. However, the subsequent
statistical power analyses (the probability of correctly rejecting a
false null hypothesis [33]) of these tests supported reliable (above
0.8 power) differences only in the ACTH-induced cortisol,
Figure 1. Haplotype tree of CYP21A2 intron 2 and the 59-part of exon 3, and the CYP21A2 haplotype clusters with multiple
significances found by tree scanning, and p-values of the haplotype clusters related to different steroid hormone levels in subjects
with non-functioning adrenal incidentaloma. Circles represent the CYP21A2 intron 2 and the 59-part of exon 3 haplotypes, lines with or without
small black circles indicate the allele differences (character-state changes) between haplotype variants and gray shapes encompass the haplotype
clusters with multiple significances. The values without parentheses are uncorrected p-values, and the values with parentheses are the corrected
step-down permutational p-value after enforcing monotonicity. ACTH – adrenocorticotrophic hormone.
doi:10.1371/journal.pone.0107244.g001
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ACTH-induced 17-OHP and metyrapone-blocked 11-deoxycorti-
sol levels (Table 2). There was an obvious tendency to differences
in ACTH-induced steroid hormone levels between the genotype
groups (Figure 2), and the multivariate ANOVA test of normal-
ized ACTH-induced cortisol, ACTH-induced aldosterone and
ACTH-induced corticosterone levels showed a significant differ-
ence (p= 0.0213, power = 0.8358).
Figure 2. Concentrations of hormones in blood decomposed by CYP21A2 intron 2 haplotype carrier groups in subjects with non-
functioning adrenal incidentaloma. c5/o and c8/o indicate the carriers (heterozygotes) of c5 and c8 haplotypes, respectively, and o/o
abbreviates the genotypes of other haplotypes. Boxes indicate interquartile ranges, lines in boxes show the medians, whiskers represent the 5 –95thth
percentiles, asterisks above the boxes indicate the significant differences between the hormone levels of genotypes. One, two and three asterisks
indicate p,0.05, p,0.01 and p,0.001 respectively (t-test or Mann-Whitney test). A) Serum cortisol level after adrenocorticotropic hormone (ACTH)
stimulation. B) Serum aldosterone level after ACTH stimulation. C) Serum 17-OH-progesterone level after ACTH stimulation. D) Serum corticosterone
level after ACTH stimulation. E) Serum 11-deoxycortisol level after metyrapone administration. F) Baseline ACTH level.
doi:10.1371/journal.pone.0107244.g002
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Relationships between hormone levels, haplotype
clusters and discrete CYP21A2 intron 2 polymorphisms
Because haplotypes consist of alleles of polymorphisms, we
expected that there should be some relationships among hormone
levels and the discrete polymorphisms of CYP21A2 intron 2.
Moreover, the genotypes of the polymorphisms were devoid of the
in silico haplotype reconstruction, and were completely deter-
mined by experiments. The relationships between the hormone
levels and the genotypes of 10 CYP21A2 intron 2 polymorphisms,
which were not in complete LD with each other (Figure S1) and
also had minor alleles occurring in more than four subjects, were
investigated in the subjects with NFAI (N= 106). Only two
polymorphisms, site 398 (g398, rs6462) and site 568 (g568,
rs41315224) showed significant differences (p,0.05) and high
power (power.0.8) simultaneously (Table S2). The prevalence of
the genotypes of g398 and the prevalence of genotypes of g568 did
not differ (Chi2 test of g398: p = 0.8736 and Chi2 test of g568:
p = 0.0874) between the subjects with NFAI and the healthy
control subjects (N= 55), and neither of polymorphisms deviated
from HWE (g398: p= 0.7560 g568: p= 0.1101) in NFAI subjects.
The deletion allele of g568 (g568del) was related to higher levels of
ACTH-induced cortisol, ACTH-induced 17-OHP and metyra-
pone-blocked 11-deoxycortisol (Table S3). The occurrence of the
alleles of g568 followed the c5 and c8 haplotype clusters; all c5
haplotypes carried only the g568del allele (LD between c5
haplotypes and g568del: r2 = 0.679), and all c8 haplotypes carried
only the g568G allele (r2 = 0.396). In addition, the genotypes
grouped by c5 and c8 haplotypes were strongly linked to the
genotypes of g568 (Chi2 test, p,0.0001) indicating the c5 and c8
haplotypes and g568 alleles described the same genetic relation-
ship. The g398C allele carriers were accompanied by higher
morning aldosterone levels (Table S3), but neither c5 haplotypes
nor c8 haplotypes harbored this allele (Table S1), and the
genotypes grouped by c5 and c8 haplotypes were not related to the
genotypes of g398 (Chi2 test p = 0.4828). Furthermore, the g398C
allele occurred in many different haplotypes, and thus this genetic
relationship could not be well described by CYP21A2 intron 2
haplotypes.
Relationships between the hormone levels, the
haplotype clusters, the g398 polymorphism and other
characteristics
We evaluated, using multiple logistic regression analysis,
whether gender, age, diameter of adenomas and BMI besides c5
haplotypes, c8 haplotypes or g398C allele might influence steroid
hormone levels proved to be significant (p,0.05) and reliable
(power.0.8). The analyses did not reveal any significant
relationship between steroid hormone levels and gender, age,
diameter of adenomas or BMI except for the association between
morning aldosterone level and age (Table 3); however, this
negative correlation has already been desribed [34]. The
relationships between c5 carriers and ACTH-induced cortisol,
ACTH-induced 17-OHP and metyrapone-blocked 11-deoxycorti-
sol levels, and the relationship between g398C carriers and
morning aldosterone level all remained significant after adjustment
for gender, age, diameter or BMI, but the relationship between c8
carriers and ACTH-induced cortisol level slightly exceeded the
significance threshold (p = 0.0690).
Discussion
Two distinct CYP21A2 intron 2 haplotype clusters, named c5
and c8, were related to the circulating steroid hormone levels in
subjects with NFAI, according to the tree scanning method. Both
T
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intron 2 haplotype clusters delineate two distinct, well-defined full-
length CYP21A2 haplotype clusters [4]; five full-length haplotypes
belong to c5, and three are assigned to c8 (Table S1). Therefore,
the relationships between hormone levels and CYP21A2 intron 2
haplotypes apply to full-length CYP21A2 haplotypes.
The carriers of c5 haplotypes showed significantly increased
cortisol, 17-OHP and 11-deoxycortisol responses to intrinsic (after
metyrapone administration) or extrinsic (ACTH administration)
elevation of ACTH levels in blood, compared to non-carriers, but
hormone levels were still in the normal range. These significant
findings were supported by high statistical power and significant
odds ratios after adjusting for gender, age, diameter of adenomas
and BMI. Moreover, the three hormonal data series were
independent, further enhancing the validity of the enhanced
ACTH response. We found in a previous study [14] that the NFAI
patients have higher cortisol and 17-OHP responses to ACTH as
healthy subjects have, but patients with subclinical Cushing’s
syndrome are not excluded from this NFAI study population, and
the ACTH-induced cortisol and 17-OHP levels are actually higher
in the previous study than those in the current one. Cortisol and
11- deoxycortisol are downstream from the steroid 21-hydroxylase
enzyme in adrenal steroidogenesis [1], and so any CYP21A2
haplotype-related differences in enzyme activity or the gene
expression level of the enzyme could directly cause the different
steroid product levels. However, there is no data on the potential
underlying molecular mechanism(s) which can support the
functional relationship between CYP21A2 allelic variants (haplo-
types) and steroid levels. The surprising polymorphism pattern of
CYP21A2 implies that the intron 2 may affect the steroid hormone
levels through gene expression [19]. The third steroid, 17-OHP,
having an elevated response to ACTH in the carriers of c5
haplotypes, is the substrate of the steroid 21-hydroxylase enzyme
and the enzyme is functionally unidirectional [1], hence the direct
effect of CYP21A2 haplotypes hardly explain the elevated 17-
OHP response. We hypothesize that the paracrine regulation of
adrenal steroidogenesis [35], either directly or indirectly activated
by higher cortisol response may the mediate elevated 17-OHP
response, and, in fact, an intraadrenal positive regulatory loop
exerted by cortisol is observed in some cases [36].
In the c8 haplotype carriers, the significant differences in
ACTH-induced cortisol level were not supported by high power
and a significant adjusted odds ratio; hence we do not regard the
relationship as a perfectly reliable one. In addition to this
reservation, the observed subtle patterns in different hormone
levels (for instance, metyrapone-blocked ACTH) might not
equivocally reflect real differences in physiological conditions,
but they could be derived from statistical reasons caused by the
relatively low number of subjects. Aside from the exact extent of
effects on different hormone levels, we consider the c5 haplotype
cluster as a causal genetic variant for the enhanced ACTH
response. A specific combination of some alleles harbored by c5
haplotypes is presumably responsible for the response rather than
one of its alleles. To the best of our knowledge, there is no
plausible explanation supporting the deviated effects of the same
CYP21A2 haplotype on hormone levels (the causal relationship
between the CYP21A2 haplotypes and steroid hormone levels is
highly probable) between the NFAI and healthy populations
(having no difference in hormone profile). Consequently, the
elevated 17-OHP response to ACTH in some healthy subjects
may render the diagnosis of non-classical CAH more difficult [37].
In addition, c5 haplotypes can potentially modify hormone levels
in patients with CAH, therefore, the genotype-phenotype corre-
lation, including the individual need for adequate hormone
substitution, may be less reliably determined. The effect of c5
haplotypes on genotype-phenotype correlation may at least to
some extent explain the reduced predictability of steroid 21-
hydroxylase deficiency [38].
We assessed the independent effects of each CYP21A2 intron 2
polymorphism, and the g398 and g568 polymorphisms showed
significant relationships with hormone levels in the blood,
supported by high statistical power. The deletion allele of the
g568 polymorphism included in the c5 haplotype showed the same
multiple significant associations with enhanced ACTH response as
c5 haplotypes and the g568 alleles correlated closely with the
genotype groups by c5 and c8 haplotypes. Therefore, g568 is not
considered as an independent genetic factor. The c5 haplotypes
always harbor the g568del allele in healthy subjects as well, and
the genotyping of the g568 polymorphism was devoid of the
in silico reconstruction of haplotypes, confirming the credibility of
results based on the combined molecular and inferred haplotyping
approach in accordance with previous confirmations [4]. Further-
more, as the g568 polymorphism resides in intron 2, it does not
affect the amino acid sequence and its direct causal effect is
disputable. The carriers of the g398C allele showed significantly
higher morning aldosterone levels, and the high statistical power
and significant odds ratio adjusted for gender, age, diameter of
adenomas and BMI supported this finding. The alleles of g398
were not related to the genotype groups by c5 and c8 haplotypes,
and were not assigned to any unique haplotypes or haplotype
clusters, implying that this or other strongly linked CYP21A2
polymorphism(s) in diverse CYP21A2 haplotype variants may be
causal.
In contrast to a previous finding [15], the CAH mutations in
subjects with NFAI were not more prevalent than those in the
healthy population, and the c5 haplotype cluster and the g398C
allele were not specifically related to NFAI. Although healthy
control subjects were not age-matched, and the prevalence of
subjects with low gene copy number of C4B decreases by age [39],
it is highly improbable that a putative shift in the prevalence of the
c5 haplotype or g398 between the subjects with NFAI and healthy
subjects could be balanced and obscured by a putative shift related
to age. The c5 haplotypes constituted the most prevalent cluster in
both NFAI and healthy subjects indicating that, one fourth of
healthy European people may have an elevated ACTH response.
In the same way, about one third of healthy Europeans may have
higher baseline aldosterone levels (but still within reference range
for aldosterone measurements) because of g398C or other
genetically linked allele(s). Therefore, the high prevalence of the
c5 haplotypes and g398C allele in the healthy population goes far
beyond the direct endocrine importance, and hence the related
elevated ACTH response and higher baseline aldosterone level
can potentially result in diverse pleiotropic effects on complex
diseases. The effects of aldosterone level on resistant hypertension
[40] and on congestive heart failure [41] are well-known. The low
copy number of C4B is associated with cardiovascular disease
(CVD) morbidity and mortality [42], as well as with the elevated
ACTH-induced serum cortisol level, suggesting that some genetic
variants of RCCX CNV, possibly c5 haplotypes, may directly
influence the individual adaptation to stress [20]. Therefore, the
causal effect of c5 haplotypes on CVD morbidity and mortality
throughout the elevated ACTH and stress responses is quite
plausible. While a full hormonal workup of healthy volunteers with
ACTH stimulation and metyrapone tests would not be ethically
acceptable [22], baseline hormone measurements need to be
repeated in different study populations.
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Supporting Information
Figure S1 Linkage disequilibrium (LD) map of dimor-
phic polymorphisms along the intron 2 and the 59-end of
exon 3 of the CYP21A2 gene in subjects with non-
functional adrenal incidentaloma. The polymorphisms are
numbered from the start of the CYP21A2 coding region in the
sequence of NT_007592.15: 31945792–31949720, dbSNP ID are
also represented. LD values are expressed in r2, and darker
background color indicates higher LD. Polymorphism 605
(rs6451) is not represented because this visualization can handle
only dimorphic polymorphisms. Some previously described
polymorphisms were absent in the current dataset because their
minor alleles are rare or occur only in the haplotypes which were
excluded due to the harbored congenital adrenal hyperplasia
mutations.
(TIF)
Table S1 Haplotypes of CYP21A2 intron 2 and the 59-end
of exon 3. CYP21A2 - steroid 21-hydroxylase gene, NFAI - non-
functional adrenal incidentaloma.
(DOC)
Table S2 Statistical significances (p-values) between
hormone levels of the genotypes of discrete CYP21A2
intron 2 polymorphisms in subjects with non-functional
adrenal incidentaloma. ACTH – adrenocorticotrophic hor-
mone. Statistical significances of t-tests, Mann-Whitney tests,
ANOVAs and Kruskal-Wallis tests were investigated in discrete
CYP21A2 intron 2 polymorphisms which were not in complete
linkage disequilibrium with each other, and had minor alleles
occurring in more than four subjects. Genotype groups which did
not exceed 4 individuals were also not taken into account.
Significant p values are followed by the values of power. Statistical
significances (p,0.05) and high power (power.0.8) are highlight-
ed with bold characters.
(DOC)
Table S3 Relationship between hormone levels and the
frequent genotypes of site 398 and site 568 in subjects
with non-functional adrenal incidentaloma. ACTH –
adrenocorticotrophic hormone. CC genotype of site 398 (N= 4)
and 2/2 genotype of site 568 (N= 1) did not exceed 4 group
members, hence they were not taken into account. The
normalities of hormone datasets were checked by the Kolmo-
gorov-Smirnov (K-S) test, and the datasets passing the normality
test were investigated with the t-test, whereas the datasets not
passing the K-S test were examined by the Mann-Whitney test.
Median values are represented, interquartile ranges are shown in
parentheses below the median values, ns; non-significant result,
significant hormone levels (p,0.05) with high power (power.0.8)
are highlighted with bold characters.
(DOC)
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